Biosimilars Could Be An Unlikely Boost For Pfizer Seeking Alpha In this same earnings call Pfizer CEO also mentions that they are working on 3 other biosimilars but they are not nearly as far along on those molecules as Trastuzumab and Rituximab. As an investor in Pfizer this is exciting news. I have written on the ... |
